Givaudan Profit Rises, Names New CFO — Update
By Nina Kienle
Givaudan backed its 2025 targets after profit grew in the first six months of the year, and named a new chief financial officer.
The Swiss flavor-and-fragrance company said Stewart Harris will succeed Tom Hallam, who will retire on Jan. 31. Harris is currently head of corporate finance and business development.
Givaudan on Tuesday posted net profit of 588 million Swiss francs ($660.9 million) for the six months ended June, up from CHF449 million in the same period the prior year. Sales rose to CHF3.74 billion from CHF3.53 billion.
Operating income rose 24% to CHF729 million while earnings before interest, taxes, depreciation and amortization rose 19% to CHF906 million.
Analysts expected net profit, Ebitda and sales at CHF533 million, CHF901 million, CHF3.7 billion, respectively, according to consensus estimates provided by the company.
With comparative figures in the second half of the year getting tougher, there might be some initial disappointment versus high expectations and also reflecting the retirement of a well-respected CFO, the analysts said.
Shares trade 4.3% lower, with peers Symrise and DSM also trading down 2.5% and 0.9%, respectively.
Givaudan reaffirmed its 2025 targets.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
July 23, 2024 05:32 ET (09:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks